Cardiff Oncology, Inc.
No enriched coverage for $CRDF in the last 7 days.
No SEC Form 4 filings for $CRDF in the last 30 days.
See all $CRDF insider activity →Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated m
Investing.com reported U.S. insider trading for July 16, 2026. Major buys included Boundless Bio (63,969 shares, about $155.6k), ADIAL Pharmaceuticals (3,233 shares, $8,690), FIS (1,386 shares, $57.4k) and Cardiff Oncology (34,364 shares plus warrants). Major sells included Celcuity (3.1M shares, about $317.8M), Arista Networks (300k shares, about $54.2M), Butterfly Network (4.0M shares, about $29.4M), CoreWeave (307,692 shares, about $24.8M) and Venture Global (555,556 shares, about $14.3M).
PACE GARY W purchased 687,285 shares of Cardiff Oncology, Inc. (CRDF) at $1.46 ($1.00M total) on 2026-07-14.
Recent CRDF coverage spans insider activity, corporate actions and financial news.
The filing combines clinical upside (Phase 2 dose/regimen selection) with a financing constraint (need for additional capital to start Phase 3).
Insider buying plus warrants can be interpreted as confidence, but the article does not provide new clinical or financial data.
The filing signals insider buying, but it is not a fundamental catalyst like earnings, trial results, or guidance.
A small open-market insider buy by the CEO, with no 10b5-1 plan cited, may modestly support sentiment but is unlikely to change fundamentals.
The filing signals a new equity-linked financing arrangement, which can pressure near-term valuation via dilution risk and warrant overhang.
alphai scores every news story that mentions CRDF with an AI model for sentiment and relevance, and aggregates insider trades from Cardiff Oncology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated m
6 min readInvesting.com reported U.S. insider trading for July 16, 2026. Major buys included Boundless Bio (63,969 shares, about $155.6k), ADIAL Pharmaceuticals (3,233 shares, $8,690), FIS (1,386 shares, $57.4k) and Cardiff Oncology (34,364 shares plus warrants). Major sells included Celcuity (3.1M shares, about $317.8M), Arista Networks (300k shares, about $54.2M), Butterfly Network (4.0M shares, about $29.4M), CoreWeave (307,692 shares, about $24.8M) and Venture Global (555,556 shares, about $14.3M).
4 min readPACE GARY W purchased 687,285 shares of Cardiff Oncology, Inc. (CRDF) at $1.46 ($1.00M total) on 2026-07-14.
2 min readMohindru Mani (Chief Executive Officer) purchased 34,364 shares of Cardiff Oncology, Inc. (CRDF) at $1.46 on 2026-07-14.
2 min readCardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 5 crdf-ex10_1.htm EX-10.1 EX-10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 14, 2026, between Cardiff Oncology, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified on the signature p
6 min readCardiff Oncology (Nasdaq: CRDF) announced a $10 million registered direct offering. It will sell 8,571,429 common shares with warrants at $1.05 per share, plus insider participation of 731,707 shares at $1.435 per share. Warrants exercise at $1.31, exercisable after six months and stockholder-authorized share increase. Closing expected July 16, 2026.
3 min readMohindru Mani (Chief Executive Officer) purchased 24,703 shares of Cardiff Oncology, Inc. (CRDF) at $1.21 on 2026-06-18.
2 min readPACE GARY W purchased 30,000 shares of Cardiff Oncology, Inc. (CRDF) at $1.22 on 2026-06-18.
2 min readCardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001213037 false 0001213037 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11,
2 min readCardiff Oncology, Inc. (CRDF) has filed a lawsuit against Nerviano Medical Sciences S.r.L (NMS) to dispute an alleged material breach of their license agreement for the drug onvansertib. NMS claimed breach because Cardiff Oncology did not name an NMS employee as a joint inventor on certain patents and would not agree to file a joint invention continuation patent application. Cardiff Oncology maintains that it did not breach the agreement and that the agreement does not require naming NMS employees on inventions made exclusively by Cardiff Oncology.
3 min read
